New ETF Book by Larry Connors - Click here to read more
"These two highly-skilled professionals fill key management positions at AspenBio as we advance our lead products toward commercialization," said the company's chairman and chief executive officer, Daryl Faulkner. "Andy brings years of animal health experience to help focus and guide our strategy for this business unit. And Mary's skill set will create a solid quality process foundation as we develop and bring to market our AppyScore(TM) diagnostic test for human appendicitis."
Dr. Peters brings to AspenBio Pharma more than 30 years of experience in the animal health market, including significant experience successfully completing regulatory, business development, strategic alliance and technology transfer activities. During his eight years with Pfizer Animal Health, he served in a number of senior positions and lastly as senior director of EU Vaccine R&D. He previously was a professor of animal health and production at the Royal Veterinary College of University of London from 1993 to 1998. Dr. Peters is a veterinarian with PhD and DSc degrees in animal science and holds a special professorship with the University of Nottingham. He has authored more than 145 papers in physiology, animal science and vaccine development, and has published two books. He is also a frequent speaker within the industry.
Dr. Nunnally joins AspenBio with 20 years experience in quality and operations management in the medical device, biomedical research product and pharmaceutical industries. Most recently, she spent nearly three years at Ceragenix Pharmaceuticals, Inc., serving as its director of technical operations, and previously spent five years with Invitrogen Corporation, lastly as its director of global supplier quality. Prior to entering industry, Dr. Nunnally spent six years on the research faculty in Physiology and Pharmacology at the University of Texas Southwestern Medical Center at Dallas. She has a B.A. in genetics from the University of California, Berkeley and a PhD in biochemistry from The Johns Hopkins University School of Medicine.
About AspenBio Pharma
AspenBio Pharma, Inc. (NASDAQ: APPY | Quote | Chart | News | PowerRating) is an emerging bio-science company dedicated to the discovery, development and commercialization of novel products that address unmet diagnostic and therapeutic needs in both human and animal health. The company's AppyScore blood-based test addresses the difficult challenge of diagnosing human appendicitis in the hospital emergency department. The company is also advancing unique therapeutic proteins designed to improve reproduction in non-companion animals of economic importance. For more information, go to www.aspenbiopharma.com.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the company's actual results to vary materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the company believes are appropriate in the circumstances. Meaningful factors, which could cause actual results to differ from expectations, many of which are beyond the control of the company, include, but are not limited to, our ability to successfully complete the clinical trial data assessments required for FDA submission, obtain FDA approval for, cost effectively manufacture and generate revenues from, the appendicitis test in development, as well as the animal products and other new products developed by the company, and our ability to retain the scientific management team to advance the products in development, execute agreements to provide the company with rights to meet its objectives, overcome adverse changes in market conditions and the regulatory environment, and obtain and enforce intellectual property rights. The company does not intend (and is not obligated) to update publicly any such forward-looking statements. For other factors that may impact such forward-looking statements, reference is made to our annual and quarterly reports filed with the Securities and Exchange Commission.
Company Contact: Jeff McGonegal CFO AspenBio Pharma, Inc. Tel 303-794-2000, ext 218 Investor Relations: Liolios Group, Inc. Ron Both or Geoffrey Plank Tel 949-574-3860 Email: Email Contact
SOURCE: AspenBio Pharma, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=752C24A7FF3180EF
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
